ubs raises price target for sartorius stedim to 215 euros

UBS has raised its price target for Sartorius Stedim Biotech from 194 euros to 215 euros after the company's third-quarter figures were released.

The Swiss bank has kept its "Neutral" rating on the stock, with analyst Matthew Weston stating that the revised target is due to higher valuations in the biotechnology sector.

The updated price target reflects a positive outlook for Sartorius Stedim, which has demonstrated resilience in its financial performance.

Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings